- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
RegCell Hires Michael McCullar as CEO
Company’s new leader previously served in the same role at OnQuality Pharmaceuticals.
RegCell, a biotech company, revealed that it has officially appointed Michael McCullar as CEO and representative director. Previously, he served as CEO of OnQuality Pharmaceuticals, where he provided executive leadership to this targeted oncology supportive therapy company focused on developing pioneering medications tailored to address the intricacies of cancer treatment-related toxicities.
"I am honored to join this remarkable team at an exciting time for RegCell as we prepare to enter the clinical stage and to support the company's mission to discover innovative treatments for autoimmune diseases," said McCullar. "In an era where the increasingly aging population is facing an escalating burden of autoimmune disorders, Treg-based cellular therapies are opening the doors to exciting new treatment possibilities. I look forward to contributing my expertise towards validating the promising potential of our regulatory T cell platform and expanding our U.S. footprint as we advance our programs towards the clinic in 2024."
Reference: RegCell Appoints Experienced Life Science Executive and Entrepreneur Michael McCullar, Ph.D., MBA, as its New Chief Executive Officer. PR Newswire. October 19, 2023. Accessed October 19, 2023. https://www.prnewswire.com/news-releases/regcell-appoints-experienced-life-science-executive-and-entrepreneur-michael-mccullar-phd-mba-as-its-new-chief-executive-officer-301961646.html
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
